Michael Benkowitz sold $3.0M of UTHR
PRESIDENT AND COO at UNITED THERAPEUTICS Corp. 9,679 shares at an average of $311.99, traded Mar 3, 2025, filed Mar 4, 2025.
Score components
- +20RolePresident
- +25Trade size$3.0M at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001562180-25-001989, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 3, 2025 | MOption exercise Common Stockindirect: by Trust10b5-1 | +7,179 | $111.00 | $797k | 7,179 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -1,300 | $308.66 | $401k | 5,879 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -2,010 | $309.69 | $622k | 3,869 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -550 | $310.54 | $171k | 3,319 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -250 | $311.74 | $78k | 3,069 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -843 | $313.33 | $264k | 2,226 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -1,026 | $313.98 | $322k | 1,200 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -122 | $315.49 | $38k | 1,078 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -578 | $316.97 | $183k | 500 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -363 | $317.93 | $115k | 137 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -137 | $318.82 | $44k | 0 | Mar 4, 2025 |
| Mar 3, 2025 | MOption exercise Common Stockindirect: by Trust10b5-1 | +2,500 | $111.00 | $278k | 2,500 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -400 | $308.99 | $124k | 2,100 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -800 | $309.82 | $248k | 1,300 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -300 | $311.01 | $93k | 1,000 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -600 | $313.93 | $188k | 400 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -300 | $317.41 | $95k | 100 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -100 | $318.70 | $32k | 0 | Mar 4, 2025 |
| Mar 3, 2025 | MOption exercise Stock Optionderivativeindirect: by Trust10b5-1 | -7,179 | $0.00 | $0 | 0 | Mar 4, 2025 |
| Mar 3, 2025 | MOption exercise Stock Optionsderivativeindirect: by Trust10b5-1 | -2,500 | $0.00 | $0 | 2,000 | Mar 4, 2025 |
Related signals
Other insiders at UNITED THERAPEUTICS Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.5M 9,500 shares | -3% | |
| 18Weak | UNITED THERAPEUTICS Corp | Paul A Mahon EVP & GENERAL COUNSEL | $4.7M 8,300 shares | -16% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $3.9M 7,580 shares | -2% | |
| 38Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $1.1M 1,920 shares | -1% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.5M 9,500 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.